Home›Trial›NCT05907954
🔬NCT05907954Phase 2ACTIVE NOT RECRUITING

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Study Summary

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Conditions
Uveal Melanoma
Interventions / Drugs
Darovasertib
View on ClinicalTrials.gov ↗
Sponsor
IDYA
IDEAYA Biosciences
Precision Oncology
D38/100
Study Details
Enrollment160 participants
Primary Completion—
Lead SponsorIDEAYA Biosciences
Data Retrieved2026-04-11 04:16:36.812153+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.